PharmaCyte Biotech successfully monetizes Femasys stake
Shares of Las Vegas, USA-based PharmaCyte Biotech (Nasdaq: PMCB) rose 25% by close yesterday, after it announced the successful monetization of its stake in Femasys (Nasdaq: FEMY), further validating the company’s strategic approach to capital deployment and strengthening its already solid financial position.
Following the monetization of the stake, PharmaCyte’s cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 2025. This transaction highlights the company’s ability to identify and execute on high-quality opportunities that deliver strong returns while maintaining a conservative risk profile.
The stake sale comes on the heels of the company increasing its stake in Q/C Technologies, formerly TNF Pharmaceuticals, in September by an additional $3 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze